trial

An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

NCTId NCT06067984
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 73 (actual)
Sponsored by Click Therapeutics, Inc.
Primary completion 2025-06-13
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
73 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2023-09-12
Primary completion
2025-06-13
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Study App

Sponsors

Click Therapeutics, Inc.Lead Sponsor
Boehringer IngelheimCollaborator

Investigators

1
Viveca Livezey, MDStudy Director

Sites

1 total
New York, United States

Linked catalysts

1
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment — primary completion2025-06-13

Facts & assertions

4 sourced
Enrollment
73
Phase
PHASE3
Primary Completion Date
2025-06-13
Status
COMPLETED
relationships
The graph out of here
drug
Study App
drug
lead_sponsor
Click Therapeutics, Inc.
company
collaborator
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Negative Symptoms in Schizophrenia
indication
Schizophrenia
indication
investigator
Viveca Livezey, MD
person